Stockwinners Market Radar for March 20, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT Cathie Wood's ARK Investment bought 41K shares of Microsoft today

20:28 EDT Enovix director buys $757K in common stock - In a regulatory filing, Enovix disclosed that its director Thurman Rodgers bought 69.6K shares of common stock on March 20th in a total transaction size of $757.

19:08 EDT Snap CFO sells $539K in common stock - In a regulatory filing, Snap disclosed that its CFO Derek Andersen sold 49.2K shares of common stock on March 16th in a total transaction size of $539.2K.

18:25 EDT First Majestic falls 17% after announcing cost cuts, suspended mining activity

18:02 EDT Canadian National, Unifor reach tentative agreements - Canadian National announced that new tentative collective agreements have been reached between Unifor and CN. The collective agreements cover approximately 3,000 CN employees working in various departments such as Mechanical, Intermodal, Facility Management, and in clerical positions in Canada. No details of the tentative agreements will be released publicly until the agreements are ratified.

17:47 EDT Charles Schwab director buys $200K in common stock - In a regulatory filing, Charles Schwab disclosed that its director Gerri Martin-Flickinger bought bought 3.7K shares of common stock on March 17th in a total transaction size of $200.4K.

17:37 EDT OpenAI-powered app from Nuance will instantly transcribe patient notes - Nuance Communications, a Microsoft Company, announced Dragon Ambient eXperience or DAX Express, a workflow-integrated, fully automated clinical documentation application that is the first to combine proven conversational and ambient AI with OpenAI's newest and most capable model, GPT-4. Extending the proven Dragon Medical portfolio of solutions and building on the market-leading DAX ambient solution launched in 2020, DAX Express is the next milestone in Nuance's long-standing mission to reduce administrative burden and empower clinicians to spend more time taking care of patients and less time on paperwork. .. Using a unique combination of conversational, ambient, and generative AI, DAX Express automatically and securely creates draft clinical notes in seconds for immediate clinical review and completion after each patient visit in the exam room or via telehealth patient conversations. Clinicians will benefit from the seamless capabilities of Dragon Medical One, DAX, and DAX Express, which are tightly integrated into the electronic medical record, beginning from pre-visit through post-encounter, reducing cognitive burdens and helping increase the joy of practicing medicine. "Nuance and Microsoft came together with the goal of helping to digitally transform healthcare, and we are marking the next step forward in the ongoing evolution of AI-powered solutions for overburdened care providers," said Mark Benjamin, CEO of Nuance. "We've taken the power and advanced reasoning capabilities of GPT-4 and integrated it into our proven outcomes-focused AI technologies in a tested and responsible way. Our state-of-the-art blend of conversational, ambient, and generative AI will accelerate the advancement of the care delivery ecosystem beyond what Nuance or Microsoft could have achieved separately - expanding our comprehensive portfolio of solutions that fulfill our vision to improve care quality and support enhanced outcomes for generations to come." Reference Link

17:22 EDT TTEC Holdings CFO Dustin Semach to leave, Francois Bourret named interim CFO - On March 14, Dustin J. Semach, TTEC Holdings CFO, notified TTEC that he is leaving the company effective April 14, to pursue another opportunity. Semach confirmed that his departure is not triggered by a disagreement with the company, its management, the board of directors, or the company's auditors on any matter relating to the company's operations, policies or practices. On March 17, pursuant to a previously established succession and continuity of management plan, the company appointed Francois Bourret, TTEC senior vice president and global controller, as the interim CFO of the company, effective April 14. Bourret joined TTEC in 2016, as part of TTEC's acquisition of Atelka, a Canadian customer care outsourcing company, where he served as the CFO and a member of the board of directors. Prior to Atelka, Bourret worked for Kilmer Capital Partners, a private equity fund, and for KPMG.

17:02 EDT Sprouts Farmers Market acquires two licensed stores in California - Sprouts Farmers Market announced that it has acquired two independently owned stores in Chula Vista, California, operating under the Sprouts Farmers Market name pursuant to a legacy trademark license arrangement. Acquiring these stores will allow complete control of the Sprouts brand and open further expansion possibilities in Southern California. The Company licensed the Sprouts Farmers Market trademark to a third-party operator many years ago in a one-of-a-kind operating structure. No other licensed Sprouts stores exist. "We are pleased to bring these two high-volume stores into the Sprouts fold, allowing us to serve more customers in the San Diego market," said Chip Molloy, chief financial officer of Sprouts Farmers Market. The stores were not factored in its outlook, released on March 2, 2023.

17:00 EDT Maui Land & Pineapple names Race Randle as CEO and Scot Sellers as Chairman - The company states: "Maui Land & Pineapple announced the appointment of Race Randle as CEO and Scot Sellers as Chairman, effective April 1, 2023. Warren Haruki, who led the company for the past 14 years, will continue to serve as a senior advisor, assisting Race and Scot as they assume their new roles."

16:57 EDT Liberty SiriusXM CEO buys $1.34M in common stock - In a regulatory filing, Liberty SiriusXM disclosed that its CEO Gregory Maffei bought 50K shares of common stock on March 16th in a total transaction size of $1.34M.

16:34 EDT Feutune Light Acquisition intends to extend deadline for business combination - Feutune Light Acquisition announced that it received notice from Feutune Light Sponsor LLC, the company's sponsor, of the Sponsor's intention to extend the period of time the company will have to consummate its initial business combination by three months from the current deadline of March 21 until June 21, subject to the timely depositing into the trust account of the company, an aggregate of $977,500, on or prior to March 21. The company was notified by the Sponsor that they intend to wire the Extension Deposit on timely basis to effectuate the Extension on March 21.

16:32 EDT WhiteHorse Finance says no exposure to Silicon Valley Bank or Signature Bank - WhiteHorse Finance (WHF) provided an update on the impact of recent events concerning Silicon Valley Bank (SIVB) and Signature Bank (SBNY) on the company, its portfolio and its Adviser. Based on a preliminary assessment conducted on March 15, the company and its investment adviser H.I.G. WhiteHorse Advisers, a subsidiary of H.I.G. Capital, have determined that each of WhiteHorse Finance and the Adviser have no exposure to SVB or SBNY; specifically, neither entity holds any cash or restricted cash balances with SVB or SBNY nor has any lending agreements with either bank.

16:31 EDT Silvergate Capital receives non-compliance notice from NYSE - Silvergate Capital announced that on March 17, 2023 it received a letter from the New York Stock Exchange notifying the Company that it is not in compliance with the NYSE's continued listing standards given the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2022. Although Company management has been working diligently to complete required information for the Form 10-K, and a substantial part of such information has been completed, the Company needs additional time to complete tasks related to its Form 10-K and its independent registered public accounting firm requires more time to obtain further information from the Company and complete certain audit procedures. The NYSE will monitor the status of the Company's late filing and related public disclosures for up to a six-month period from its due date. If the Company fails to file its delayed filing and has any subsequent delayed filings within six months from the filing due date, the NYSE may, in its sole discretion, allow the Company's securities to trade for up to an additional six months depending on specific circumstances, as outlined in Section 802.01E of the Listed Company Manual. If the NYSE determines that an additional six-month trading period is not appropriate, suspension and delisting procedures will commence.

16:31 EDT Gamida Cell board names Shawn Cline Tomasello chairwoman - Gamida Cell announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. "On behalf of my fellow board members and Gamida Cell's employees, I want to thank Robert for his dedicated service to this company," said Abbey Jenkins, Gamida Cell President and Chief Executive Officer. "Robert has been a tireless advocate for Gamida Cell for the past five years and has provided strong oversight through many critical decisions. Shawn is a highly respected and seasoned biotech executive with tremendous experience in all dimensions of our industry, including corporate strategy and commercialization of innovative hematology, oncology and cell therapies. We look forward to her leadership as we approach our May 1 FDA target action date for omidubicel and, if approved, shift our focus to commercialization." In addition, the company announced the resignations of Dr. Anat Cohen-Dayag and Dr. Naama Halevi-Davidov. Both joined the Board in January 2022. Dr. Cohen-Dayag chaired the Science and Technology Committee and served on the Nominating and Governance Committee. Dr. Halevi-Davidov was a member of the Audit Committee.

16:21 EDT Ritchie Bros. completes acquisition of IAA - Ritchie Bros. (RBA) announced that it has completed its acquisition of IAA (IAA). As previously announced on January 23, under the terms of the amended merger agreement, IAA shareholders will receive $12.80 per share in cash and 0.5252 common shares of Ritchie Bros. for each share of IAA common stock they own. As a result of the completion of the transaction, IAA's common stock ceased trading on the New York Stock Exchange under the ticker symbol "IAA" as of the close of trading on March 20.

16:15 EDT Harmonic jumps 8% to $14.20 after technology partnership with Charter

16:14 EDT Cipher names Patrick Kelly and Will Iwaschuk co- presidents, Stennett as CAO - Cipher Mining announced that Patrick Kelly and Will Iwaschuk have been promoted to Co-President, and that Olivia Stennett has been promoted to Chief Administrative Officer. As Co-Presidents, Mr. Kelly and Mr. Iwaschuk will lead and scale Cipher's growth and business operations, including bitcoin mining and potential adjacent opportunities. They will continue to report to Cipher's Chief Executive Officer, Tyler Page. As Chief Administrative Officer, Ms. Stennett will lead Cipher's corporate administrative functions as the Company continues its rapid growth. She will continue to report to Mr. Iwaschuk."At all levels, Cipher's team is its greatest competitive advantage, and we are fortunate to have all three of these talented leaders," said Page.

16:11 EDT Great Lakes Dredge announces receipt of $138.8M in awarded work - Great Lakes Dredge & Dock Corporation announced the receipt of several major dredging awards totaling $138.8M. The Trujillo Alto Design and Build for the Lago Loiza Dredging Project includes dredging in the reservoir area, preparation and construction of the work area, and storage and handling of materials. The project also includes the preparation and rehabilitation of disposal areas for the extracted sediments, installation of sediment pumping pipes from the dredging area in the reservoir to the disposal areas of dams, and the management of dredged sediments in the dike area and disposal of clarifed water back to the reservoir. The dredging of the Carraizo reservoir, which is located in the Rio Grande de Loiza, is the largest source of drinking water supply for the area. This project will benefit approximately 171,387 families in the Municipalities of San Juan, Trujillo Alto. The client on this project is the Puerto Rico Aqueduct & Sewer Authority and is funded by the Federal Emergency Management Agency . Work is expected to commence in the Spring of 2023 with estimated completion in the Spring of 2025.The Townsends Inlet to Cape May Inlet Project, awarded in December of 2022, consists of beachfill placement along the Atlantic Ocean coastline in the Boroughs of Avalon and Stone Harbor, New Jersey to restore beaches and protect the shoreline. The client on this project is the U.S. Army Corps of Engineers, Philadelphia District and is federally funded. Work is expected to complete in the Spring of 2023. The Palm Beach Harbor Maintenance Dredging Project entails dredging material from the entrance channel and settlement basin and beneficially placing material on the adjacent beach. The client on this project is the U.S. Army Corps of Engineers and is federally funded. Work was started and completed in the first quarter of 2023. The South Boca Raton Beach Renourishment Project entails the placement of sand along the beach beginning at the Boca Raton Inlet and extending to the Palm Beach County border as well as open options for beach renourishment at Hillsboro and Deerfield beaches. The client on this project is South Boca Raton and is locally funded. Work is expected to complete in the Spring of 2023.Dave Johanson, Senior Vice President, Project Acquisitions and Operations for Great Lakes commented, "Great Lakes is pleased to add the above projects to our backlog of coastal protection and maintenance dredging projects. We continue to see severe weather batter our coasts, so there is a great need for the above listed projects and similar projects to continue to support the overall improvement and resiliency of our country's environment, coastlines and infrastructure."

16:08 EDT Grindrod Shipping interim CEO, CFO Stephen Griffiths to retire - Grindrod Shipping announced the following changes to its executive management and board. Effective from March 31, Stephen Griffiths will be retiring from the company as interim CEO and CFO after more than 13 years of service with Grindrod Shipping and its predecessors. Griffiths will also retire from his board position at the company. Concurrently, the board of directors has appointed Edward Buttery as CEO and Deborah Davel as CFO, effective April 1. Buttery will remain on the board as an executive director but will relinquish his position as a compensation and nomination committee member. Also effective from March 31, Quah Ban Huat and John Herholdt will be retiring as directors of the company in accordance with the terms of the previously announced transaction implementation agreement with Taylor Maritime. Quah will also be relinquishing his position as chairman of the audit and risk committee, or ARC, and Herholdt will be relinquishing his position as chairman of the CNC. In conjunction with their departures, the board has appointed Gordon French as an independent, non-executive director and a member of the ARC. French will be appointed as the new ARC chairman effective on April 1. Existing independent non-executive director Cullen Schaar will be appointed as the new CNC chairman effective on April 1.

16:08 EDT First Trust raises quarterly dividend to 5.25c per share from 4.5c - The distribution will be payable on April 17, 2023, to shareholders of record as of April 4, 2023.

16:06 EDT Four Corners Property Trust acquires WellNow Urgent Care for $2.2M - Four Corners Property Trust announces the acquisition of a WellNow Urgent Care center for $2.2 million. The property is located in a strong retail corridor in Indiana and is corporate-operated. The transaction was priced at a cap rate in range with previous FCPT transactions.

16:00 EDT Cyclo Therapeutics says in preliminary talks with potential strategic parties - In a regulatory filing, Cyclo Therapeutics announced that the company was in preliminary discussions with a number of potential strategic parties, "including with respect to a business combination that could provide the company with substantial capital." The company added: "However, the consummation of any such transaction would be subject to the negotiation and execution of definitive agreements containing customary conditions to closing. In addition, proceeding with the potential business combination would require that certain security instruments of the company be amended to eliminate the company's obligation to make a cash payment to the holders of such securities upon the consummation of a change in control transaction. There can be no assurance that any such transaction will be consummated."

14:03 EDT Newell Brands credit rating cut to junk by S&P Global - S&P Global Ratings lowered its long-term issuer credit rating on Newell Brands to "BB+" from "BBB-" saying the company's earnings and cash flow guidance for fiscal year 2023 is "significantly weaker" than previous expectations because of weak macroeconomic conditions and continued inflationary pressures. Newell has a publicly stated a 2.5 times net leverage financial policy target, but its capital allocation decisions, combined with weaker demand for its products from a challenging macroeconomic backdrop, have increased its debt over the last year, S&P said in a statement.

13:31 EDT Amazon's Twitch lays off just over 400 staff - Amazon's Twitch said that it has made the "difficult decision" to reduce the size of its workforce by just over 400 people. "As a company focused on building community together, this decision was incredibly difficult and one we did not make without considerable thought," the company said. Reference Link

13:24 EDT Graybug changes name to CalciMedica, ticker to 'CALC' - Graybug Vision (GRAY) announced that it has changed its name to CalciMedica, Inc., which will become effective at 4:02 pm ET. In connection with the name change, the company has changed its trading symbol to "CALC." The company's common stock will commence trading on March 21 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica.

13:02 EDT Portland General Electric names Benjamin Felton as COO - Portland General Electric announced the appointment of Benjamin Felton as the company's new Chief Operating Officer, effective April 3. "In his role, Felton will lead the utility operations groups, including generation, distribution, engineering, project management, environmental, construction, safety and other operations-focused areas... Felton comes to PGE with more than 30 years of energy industry experience with Consumers Energy, NiSource and DTE. He was most recently the senior vice president of Energy Supply at DTE," the company stated.

12:12 EDT First Republic extends decline, shares down 37% to $14.59

12:00 EDT Dingdong falls -16.0% - Dingdong is down -16.0%, or -64c to $3.36.

12:00 EDT Bank United Corporation rises 9.8% - Bank United Corporation is up 9.8%, or $1.40 to $15.71.

12:00 EDT New York Community Bancorp rises 34.9% - New York Community Bancorp is up 34.9%, or $2.29 to $8.82.

10:48 EDT OCC conditionally approves Flagstar to buy, assume deposits of Signature - The Office of the Comptroller of the Currency announced Monday that it has conditionally approved Flagstar Bank, N.A. (NYCB), Hicksville, New York, to purchase assets and assume certain liabilities of Signature Bridge Bank, N.A. (SBNY), New York, New York. The transaction includes the purchase by Flagstar Bank of certain loan portfolios from Signature Bridge Bank, N.A., that total $12.9 billion and the assumption of $34B in deposits. The OCC imposed conditions on the approval, including to require Flagstar Bank to allocate appropriate resources to the assets and liabilities acquired, and to require a supervisory non-objection prior to paying a dividend to shareholders. Signature Bank, New York, New York, was closed on March 12, 2023, by the New York State Department of Financial Services, which appointed the FDIC as receiver. After its appointment as receiver, the FDIC filed an application with the OCC to establish Signature Bridge Bank, N.A., which was approved by the OCC late that day. The FDIC then transferred substantially all of the assets and liabilities of Signature Bank to Signature Bridge Bank, N.A., operated by the FDIC, as it marketed such assets and deposits to potential bidders. The FDIC announced on March 19, 2023, that it had entered into a purchase and assumption agreement with Flagstar Bank N.A., for substantially all deposits and certain loan portfolios of Signature Bridge Bank, N.A. Reference Link

10:27 EDT Peltz says not out of Disney, but 'not in as much as we were' - Nelson Peltz of Trian Fund Management, while being interviewed on CNBC, said Trian has not sold out of its position in Disney, but its "not in as much" as it was before.

10:09 EDT Ambit Biosciences Corp trading halted, volatility trading pause

10:00 EDT KE Holdings falls -7.0% - KE Holdings is down -7.0%, or -$1.33 to $17.65.

10:00 EDT First Republic falls -12.5% - First Republic is down -12.5%, or -$2.88 to $20.15.

10:00 EDT Aspen Aerogels rises 10.7% - Aspen Aerogels is up 10.7%, or 73c to $7.54.

09:58 EDT Nuvalent NSCLC treatment granted FDA orphan designation - Nuvalent was granted FDA orphan designation for its treatment of ALK-positive, ROS1-positive, and LTK-positive non-small cell lung cancer, or NSCLC, according to a post to the agency's website. Reference Link

09:47 EDT KE Holdings falls -5.1% - KE Holdings is down -5.1%, or -97c to $18.01.

09:47 EDT Western Alliance rises 9.5% - Western Alliance is up 9.5%, or $2.97 to $34.29.

09:47 EDT New York Community Bancorp rises 39.4% - New York Community Bancorp is up 39.4%, or $2.58 to $9.12.

09:42 EDT First Republic trading resumes

09:37 EDT Bank of England issues statement, says U.K. banking system 'safe and sound' - The Bank of England issued the following statement: "The UK's bank resolution framework has a clear statutory order in which shareholders and creditors would bear losses in a resolution or insolvency scenario. This was the approach used for the recent resolution of SVB UK, in which all of SVB UK's Additional Tier 1 - AT1 - and T2 instruments were written down in full and the whole of the firm's equity was transferred for a nominal sum of GBP 1. AT1 instruments rank ahead of CET1 and behind T2 in the hierarchy. Holders of such instruments should expect to be exposed to losses in resolution or insolvency in the order of their positions in this hierarchy. The Bank welcomes the comprehensive set of actions taken yesterday by the Swiss authorities in order to ensure financial stability. The UK banking system is well capitalised and funded, and remains safe and sound." Some of the largest U.K. banks include Lloyds Banking (LYG), Barclays (BCS) and HSBC (HSBC). Reference Link

09:34 EDT AudioEye trading halted, volatility trading pause

09:20 EDT Meridian Bank reiterates two-for-one stock split - Meridian Corporation reiterates that each shareholder of record as of the close of business on March 14, 2023, will receive one additional share of Company common stock for each share then held. The shares will be distributed after the close of business today, March 20, 2023.

09:19 EDT Cue Health receives EUA from FDA for mpox virus molecular test - Cue Health announced it has received Emergency Use Authorization, or EUA, from the FDA for its molecular test to detect the mpox virus. This nucleic acid amplification test is run on a Cue Reader, can be performed at any CLIA-waived facility and delivers results in 25 minutes, significantly expanding access to fast and accurate testing for patients.

09:17 EDT Safe Bulkers board authorizes 5M stock repurchase program - Safe Bulkers has authorized a program under which it may from time to time in the future purchase up to 5,000,000 shares of the Company's common stock. If the maximum number of shares of the Company's common stock are purchased pursuant to the aforementioned program, it would represent approximately 4.3% of the shares of the Company's common stock outstanding and 6.6% of its public float. The program does not obligate the Company to purchase shares of the Company's common stock and the program may be modified or terminated at any time without prior notice. Any such purchases will be made in the open market in compliance with applicable laws and regulations, and that purchases on the open market will be conducted within the safe harbor provisions of Regulation 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases will be funded using the Company's existing cash resources. The common stock repurchase program announced today is in continuation to the program announced on June 21, 2022, pursuant to which the Company authorized the purchase of up to 5,000,000 shares of the Company's common stock. Purchases under the program announced today will commence at any time after the previously announced program is concluded.

09:15 EDT Matador director buys $196K in common stock - In a regulatory filing, Matador disclosed that its director Timothy Parker bought 4.5K shares of common stock on March 16th in a total transaction size of $196K. Shares of Matador are up 3.5% in pre-market trading at $44.95.

09:13 EDT Semtech enters into cooperation agreement with Lion Point Capital - Semtech announced that it has entered into a Cooperation Agreement with Lion Point Capital an investment firm and one of the Company's largest stockholders, with beneficial ownership of approximately 4% of Semtech's outstanding shares of common stock. Under the terms of the Cooperation Agreement, Semtech and Lion Point will confer with one another on the appointment of two independent directors to Semtech's Board of Directors, ultimately to be selected by Lion Point after receiving the views of Semtech. The new directors will be appointed within 30 days of entering into the Cooperation Agreement, at which point the Board will be expanded from 10 to 12 directors. The two new independent directors and eight current Semtech directors will stand for election to the Board at the Company's 2023 Annual Meeting of Stockholders which has not yet been scheduled. In addition, the Company will commence a search and confer with Lion Point on the appointment of two additional independent directors, ultimately to be selected by the Company after receiving the views of Lion Point. If one or both of those directors are selected prior to the 2023 Annual Meeting, they would also stand for election at that meeting.

09:11 EDT Castor Maritime announces sale of M/V Magic Rainbow for $12.6M - Castor Maritime announces that on March 13, 2023, the company entered into an agreement with a third party for the sale of the M/V Magic Rainbow at a price of $12.6 million. The conclusion of the sale agreement is subject to the execution of definitive documentation customary for this type of transaction. The vessel is expected to be delivered to its new owner during the second quarter of 2023. The Company expects to record during the second quarter of 2023 a net gain on the sale of the M/V Magic Rainbow of approximately $4.4 million, excluding any transaction related costs.

09:10 EDT Brera Holdings establishes new football club in Mozambique - Brera Holdings announced the establishment of a newly branded football club in Mozambique named Brera Tchumene, a team admitted to the Second Division Championship in Mozambique, an east African country of nearly 32 million people. This establishment follows Brera Holdings' in-process acquisition of Akademija Pandev, which is already competing in the First Division of North Macedonia, a UEFA member state. Brera Tchumene will have its training and game base in a modern sports center located in the metropolitan area of the capital city Maputo. "The team is strongly aiming for promotion to the Mocambola First Division, which would lead to greater involvement by Brera Holdings, realizing its core business in the scouting of the best Mozambican players in the 18-23 age bracket, with a view to moving these players to Europe to join the other Brera Group clubs," said Brera Holdings' CEO Sergio Scalpelli. The Brera Tchumene football club will play its debut match on April 16, 2023.

09:08 EDT Select Medical to build new specialty hospital in Orlando, Florida - Select Medical announced plans to build a new specialty hospital to include critical illness recovery and inpatient rehabilitative care in the Dr. Phillips suburb of Orlando, Florida. The state-of-the-art, 63-bed facility will be located at 7450 Sand Lake Commons Blvd. in Orlando. Expected to open in late 2024, the new Select Specialty Hospital will serve patients recovering from chronic, medically-complex conditions and debilitating illnesses as well as injuries including stroke and other neurological disorders, brain injury, spinal cord injury, amputation and other orthopedic conditions.

09:06 EDT Clearwater Analytics, BNP Paribas announce services partnership - Clearwater Analytics announced a new services partnership with BNP Paribas' Securities Services business, a global multi-asset servicing specialist with EUR 11.1T in assets under custody and EUR 2.3T in assets under administration, to offer investment accounting and reporting solutions combined with the bank's custodian services. Securities Services at BNP Paribas is a leading global custodian providing multi-asset post-trade and asset servicing solutions to buy-side and sell-side market participants, corporates, and issuers.

09:05 EDT Porch Group files application to form a reciprocal insurance exchange - Porch Group announced that its insurance business, Homeowners of America, has filed an application to form and license a Texas reciprocal insurance exchange with the Texas Department of Insurance. If approved and fully implemented by Porch, its insurance underwriting business would be conducted exclusively through the Reciprocal.The formation of the Reciprocal is an initial step in Porch's long-term strategy to reduce its exposure to earnings volatility from its Insurance segment by mitigating direct exposure to insurance claims and weather events. The Reciprocal may also help to reduce the impact of a challenging reinsurance market that has both less capacity and higher prices. Homeowners that purchase policies in the Reciprocal could receive benefits and value-added services unique to what Porch and its various companies offer. Similarly, Porch would be able to continue to pursue its growth strategy by reaching homebuyers early and throughout the homebuying journey, and leveraging access to homebuyer information and property data. A reciprocal insurer is an insurance association owned by its policyholder-members who spread risk by pooling their risks together. This reciprocal exchange structure has been utilized by other homeowner insurance businesses such as Farmers Insurance. The day-to-day operations of the Reciprocal would be managed by a subsidiary of Porch, which would receive ongoing fees for originating, underwriting and processing claims on behalf of the Reciprocal. The launch of the Reciprocal remains subject to review and approval by the TDI, which is not expected before Q3 2023. Formation of the reciprocal is subject to ongoing Porch and regulatory review in context of broader capital and operating environment and the decision to proceed remains within the Company's discretion.

09:04 EDT Mullen Automotive, Qiantu Motors to launch EV supercar - Mullen Automotive announces that it has been granted the North and South American IP and distribution rights from Qiantu Motors and affiliated companies as part of a license agreement allowing assembly and distribution of the DragonFLY K50 in the Americas. Mullen will begin its program to re-engineer and re-design the product to meet homologation requirements for U.S. certification and customer expectations for today's supercars. These modifications will be in line with Mullen's vehicle design language currently found in the Mullen FIVE and Mullen FIVE RS. "This agreement with Qiantu is an important milestone for the Company. Not only does it settle a long outstanding dispute between our respective companies, but also presents the opportunity to fulfill my vision for a supercar that would rival some of the best supercars in the world," said Mullen's CEO and Chairman David Michery. "Since day one, we have received overwhelming positive feedback for this vehicle, including our original debut at the 2019 New York Auto Show and the Indy 500 in May 2019. We are excited to start the GT and GTRS programs on March 20, 2023."

09:02 EDT INVO Bioscience to acquire Wisconsin Fertility Institute for $10M - INVO Bioscience announced it has signed binding agreements to acquire Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5M in revenue and net income of approximately $1.9M for the trailing 12-month period ended September 30, 2022. The purchase price of the acquisition is $10M payable over a three-year period. There will be an initial $2.5M due in cash at closing, with subsequent $2.5 million payments due annually for the following three years. At the discretion of the sellers, subsequent payments may be paid in cash or in shares of INVO common stock valued at $6.25, $9.09, and $14.29, for the second, third and final payments, respectively. Final closing of the transactions is expected to occur in the second calendar quarter of 2023, subject to completing customary closing procedures.

08:54 EDT Foot Locker focusing on banners, geographies that will drive growth, says CEO - President and CEO Mary Dillon is speaking at the company's Investor Day event.

08:49 EDT BioLargo says Q1 revenues surpass previous record quarterly revenues - BioLargo announced that the Company's first quarter 2023 revenues have already surpassed the Company's previous record quarterly revenues set last quarter. This revenue growth is driven primarily by sales of the Pooph branded pet-odor control product sold by Ikigai Marketing Works, LLC. Company management expects that quarter over quarter revenues in Q1 2023 will surpass a 50% growth rate over Q4 2022, will represent the seventh consecutive quarterly period of revenue growth, and that first quarter revenues will be more than four times 2022's first quarter topline revenue. This comes off the heels of its already released press release dated January 9, 2023, announcing a year over year growth rate of at least 125% for 2022 versus 2021, which represents the eighth consecutive year of revenue growth. While the Company is not yet profitable, its net losses are trending downward as revenues have increased. The Company is currently concluding its audit of its 2022 financial statements and intends to file its annual report with the SEC at the end of March. These revenue estimates for 2022 and the first quarter of 2023 are preliminary and subject to change pending review and audit by the company's independent registered public accounting firm.

08:46 EDT India Globalization Capital announces rebranding to IGC Pharma - India Globalization Capital will begin operating under the new name IGC Pharma, effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma's strategic focus and vision for the future. Common stock will continue to be quoted on the NYSE American under the same symbol IGC. Trading of common stock under the new name will commence on March 31, 2023. CUSIP and EIN numbers will remain the same.The name change to IGC Pharma, Inc. acknowledges the Company's identity as a developer of drug assets for treating diseases, including, but not limited to, Alzheimer's disease. IGC believes it has the first natural, cannabis-based, patent-protected compound that relies on low doses of THC, a psychoactive cannabinoid, and another compound as pharmaceutically active agents for the treatment of Alzheimer's disease. IGC is currently in a Phase 2 trial with its THC-based investigational medication, IGC-AD1, for the treatment of agitation in Alzheimer's. IGC-AD1 is the only natural, THC-based investigational drug candidate currently undergoing FDA trials on Alzheimer's. The APIs in IGC Pharma's leading drug asset, IGC-AD1, have shown in preclinical studies on Alzheimer's cell lines the potential to be effective in ameliorating a key protein responsible for Abeta plaques, a key hallmark of Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome, menstrual cramps and sleep disorders.

08:44 EDT Camber resolves legacy accounting issues, reduces Series C Preferred shares - Camber Energy and Viking Energy Group announced that the Board of Directors of each company resolved on or about March 14, 2023, as a result of Camber addressing certain legacy accounting issues and extinguishing, through redemptions and conversions, approximately ninety-four percent of Camber's previously issued shares of Series C Redeemable Convertible Preferred Stock, to resume negotiations and take certain steps regarding the previously announced Agreement and Plan of Merger between Viking and Camber.The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, a newly formed wholly owned subsidiary of Camber will merge with and into Viking, with Viking surviving the Merger as a wholly-owned subsidiary of Camber and Camber remaining the sole publicly-traded entity. However, given the lapse of time since the date of the Merger Agreement, Camber and Viking believe it is reasonably likely that certain terms will need to be modified by the parties in order for the parties to proceed with the Merger. The Board of Directors of each of Camber and Viking authorized, among other things, that each company re-engage separate, independent valuation firms to provide fairness opinions and/or any other valuation report, analyses or presentations that might be necessary or appropriate regarding with the Merger, engage legal counsel and other professionals or consultants, and permitted authorized representatives to communicate with authorized representatives of the other party on matters related to the Merger, including with respect to possible amendments or modifications to the Merger Agreement as the parties consider necessary or appropriate, subject in all cases to the final approval of the Board of Directors of each entity.

08:42 EDT Snail announces date change for Q4, FY22 financial results - Snail announced that is has changed its earnings release date for the fourth quarter and full year 2022 financial results to Wednesday, March 29, 2023, after the U.S. stock market closes. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss the results.

08:41 EDT Foot Locker to close stores, ecommerce in Hong Kong, Macau - As part of its efforts to simplify its business model and focus on core banners and regions, the company announced earlier that it is transforming its business model in Asia through the following actions: Closing its stores and ecommerce in Hong Kong and Macau; Converting its current owned and operated stores and ecommerce in Singapore and Malaysia to a license model; Continuing to operate stores in South Korea; and Continuing to pursue growth in the region through license partners. MAP Active, who already partners with the company in Indonesia and the Philippines, will take over the company's store and ecommerce operations in Singapore and Malaysia, and seek to grow in those markets and new markets in the region over time.

08:40 EDT PFSweb board authorizes 1M share repurchase program - PFSweb announced that its board of directors has authorized a share repurchase program, under which the Company may purchase up to an aggregate of 1,000,000 shares of its common stock. The program will be in place for up to two years. Subject to applicable rules and regulations, the shares may be purchased from time to time in the open market or in privately negotiated transactions. The share repurchase program will be conducted in accordance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. Such purchases will be at times and in amounts as PFSweb deems appropriate, based on factors such as market conditions, legal requirements, and business considerations. The share repurchase program does not require the Company to repurchase shares and can be terminated at any time. The Company intends to fund any purchases with existing cash balances and/or cash flow from operations.

08:38 EDT Navitas Semiconductor launches family of GaNSense Control ICs - Navitas Semiconductor has launched a new family of GaNSense Control ICs that deliver unprecedented levels of performance and integration. GaN is a next-generation semiconductor technology that is a significant upgrade over conventional high-voltage silicon power semiconductors, while also reducing the energy and physical space needed to deliver that performance. It runs up to 20x faster and can also enable up to three times more power handling or three times faster charging capability, in half the size and weight. Each of these power systems also require an optimized, high-speed, low-voltage silicon system controller which Navitas has developed and integrated with its high-performance GaN ICs to create the industry's first GaNSense control IC technology.

08:37 EDT CIIG Capital Partners II announces registration statement for Zapp combination - CIIG Capital Partners II announced that the U.S. Securities and Exchange Commission has declared effective the registration statement on Form F-4 of Zapp Electric Vehicles Group, which includes a definitive proxy statement/prospectus in connection with CIIG II's special meeting of stockholders to consider the previously announced proposed business combination with Zapp Electric Vehicles. Additionally, CIIG II announced that it has set a record date of February 13, 2023 and a meeting date of April 12, 2023 for its Special Meeting. CIIG II's stockholders of record at the close of business on the Record Date are entitled to receive notice of the Special Meeting and to vote the shares of common stock of CIIG II owned by them at the Special Meeting. In connection with the Special Meeting, CIIG II's stockholders that wish to exercise their redemption rights must do so no later than 5:00 p.m. ET on April 10, 2023 by following the procedures specified in the definitive proxy statement/prospectus for the Special Meeting. There is no requirement that stockholders affirmatively vote for or against the Business Combination at the Special Meeting in order to redeem their shares for cash. As announced previously, the Business Combination is to be effected through a newly created holding company, Pubco, and CIIG II and Zapp will become wholly-owned subsidiaries of Pubco upon the consummation of the Business Combination. CIIG II's Class A common stock is currently traded on Nasdaq under the symbol "CIIG." In connection with the closing of the transaction, Pubco ordinary shares and warrants will be Nasdaq-listed under the new ticker symbols "ZAPP" and "ZAPPW," respectively.The Record Date determines the holders of CIIG II's common stock entitled to receive notice of and to vote at the Special Meeting, and at any adjournment or postponement thereof, whereby stockholders will be asked to approve and adopt the Business Combination, and such other proposals as disclosed in the definitive proxy statement included in the Registration Statement. If the Business Combination is approved by CIIG II stockholders, CIIG II anticipates closing the Business Combination shortly after the Special Meeting, subject to the satisfaction or waiver of all other closing conditions. The Special Meeting will take place at 12:00 p.m., Eastern Time, on April 12, 2023 in person at the offices of Orrick, Herrington & Sutcliffe LLP, located at 51 West 52nd Street, New York, New York 10019. CIIG II encourages its stockholders entitled to vote at the Special Meeting to vote their shares via proxy in advance of the Special Meeting by following the instructions on the proxy card.

08:36 EDT SuRo Capital to commence modified dutch auction tender offer for 3M shares - SuRo Capital will commence a modified "Dutch Auction" tender offer to purchase up to 3 million shares of its common stock at a price per share not less than $3.00 and not greater than $4.50 in $0.10 increments, using available cash. "As we have consistently demonstrated, SuRo Capital is committed to initiatives that enhance shareholder value, and we believe the market is currently undervaluing our portfolio. Accordingly, on March 17, 2023, our Board of Directors authorized a modified Dutch Auction Tender Offer to purchase up to 3 million shares of our common stock at a price per share between $3.00 and $4.50. Given our stock is trading at a significant discount to net asset value, coupled with the extreme market volatility, we believe the modified Dutch Auction Tender offer to be an efficient and accretive deployment of capital," said Mark Klein, Chairman and Chief Executive Officer of SuRo Capital.

08:35 EDT Sigma Additive Solutions expands collaboration with Materialise - Sigma Additive Solutions announced that it has expanded its collaboration with Materialise to provide additive manufacturing, or AM, users automated quality control by integrating the PrintRite3D quality assurance solution into the new software solution Materialise Process Control. Sigma and Materialise collaborated to integrate PrintRite3D into Process Control and to make it available in CO-AM, Materialise's end-to-end software platform for 3D printing. Sigma's PrintRite3D suite provides in-process data, including thermal data from the melt pool, yielding layer data that can enable users to find the root cause of defects faster.

08:32 EDT Revive Therapeutics: Phase 3 study for bucillamine to retain current endpoint - Revive Therapeutics announced an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19. On March 8th, 2023, the Company announced that it had received the Type C meeting written responses from the FDA to obtain agreement on the proposed protocol endpoints for the Company's Study. The FDA recommended that the Company's proposed primary symptom-based endpoint should cover the evaluation of time to sustained recovery assessed over an appropriate duration, evidence of subjects experiencing resolution of COVID-19 related symptoms and the element of sustained symptom resolution. After a further in-depth review and analysis of the FDA recommendations with members of the Company's clinical trial team, including its statistician, regulatory affairs, medical affairs, and clinical research advisors, the Company has decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. As such, the Company will remain with the current Study protocol's primary endpoint of proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization. Although the Study was originally designed for a 'hospitalization or death' primary endpoint, and it completed enrollment of almost three-quarters of the Study's recruitment goal and recorded specific clinical symptoms, the Study was not designed to take into account all of the symptom assessments and supporting data outlined in the FDA guidelines to warrant a primary symptom-based endpoint for COVID-19 studies. With the shift in COVID-19 clinical outcomes observed over the course of the pandemic, many patients with COVID-19 were either asymptomatic or experienced mild to moderate illness and could be managed in the outpatient setting. The Company made efforts with the FDA to allow for specific primary symptom-based endpoints, which were aligned with the Study's available Pre-Dose selection data, such as time to resolution from COVID-19 via the polymerase chain reaction test and proportion of participants with improvement in at least two COVID-19 related clinical symptoms on or before Day 14. As such, it was now determined by the Company's advisors and clinical team that any deviation from the Study's original primary endpoint and any unblinding of the Post-Dose selection data of approximately 500 subjects that were randomized in the current Study would jeopardize any chance of potential future regulatory approval. As previously announced, the Data Safety Monitoring Board reviewed the Study's Post-Dose selection data and supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported.

08:32 EDT Franchise receives unsolicited proposal to be acquired for $30 per share - Franchise Group announced that it has received an unsolicited non-binding proposal, which is subject to certain conditions, to acquire all of the outstanding shares of the common stock of the Company for a price of $30.00 per share in cash. The Board of Directors will carefully evaluate the proposal to determine the course of action that it believes is in the best interests of the Company and all FRG stockholders. The Company makes no assurance that the proposal will result in a transaction.

08:30 EDT FleetCor enters into cooperation agreement with D.E. Shaw - FLEETCOR Technologies "announced it has entered into a cooperation agreement with one of its long-term shareholders, the D. E. Shaw group. As part of the agreement, FLEETCOR has appointed Rahul Gupta to the Company's Board of Directors, agreed to add another, mutually agreed-upon director to the Board and agreed to form an ad hoc Strategic Review Committee. Additionally, FLEETCOR will undertake a review of its portfolio and business configuration, with the goal of driving enhanced shareholder value. The portfolio review will assist the Board as it considers various strategic alternatives, including but not limited to the possible separation of one or more of the Company's businesses. The Company will prioritize this assessment and intends to complete the portfolio review by the end of 2023. The Company will have no further comment on the status of the review until its conclusion. This review will complement the Company's ongoing business simplification plan initiative. " Shares of FleetCor are up 5.0% in pre-market trading at $196.56 following the announcement.

08:26 EDT Franchise Group trading halted, news pending

08:24 EDT XS Financial board, management voluntarily forfeit over 25M options - XS Financial has canceled a total of 25,023,888 stock options granted to certain officers, directors, and employees of the Company. The option holders voluntarily surrendered the Canceled Options for no consideration. David Kivitz, CEO of XS Financial commented: "We are pleased to announce the board and management have approved a voluntary forfeiture of several tranches of previously granted options. We feel our share price has not reflected the strong and improving fundamentals in our business and therefore felt it appropriate to reduce previously awarded options granted to our board and management. Combined with 50,667,531 warrants which expired in March 2023, tied to our March 2021 Private Placement offering, our capitalization table has significantly improved for stakeholders."

08:22 EDT Ra Medical Systems' Catheter Precision registers VIVO in Switzerland - Ra Medical Systems announced that its wholly owned subsidiary, Catheter Precision, Inc., has registered its leading product, VIVO, in Switzerland and has completed first cases in the new territory. VIVO has already received FDA Clearance and successful registration with a German Competent Authority and MHRA registration allowing VIVO to be sold in the US, twenty-three countries within the European Union and the UK. For manufacturers based outside of Switzerland it is necessary to have a CH REP, or Swiss Authorized Representative, prior to marketing their medical devices in Switzerland.

08:20 EDT Enphase Energy expands IQ8 microinverter deployments in Virginia - Enphase Energy announced that installers of Enphase products in Virginia have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters. "Enphase is lucky to work with a vast network of experienced installers across Virginia to bring more energy independence to homeowners across the state," said Dave Ranhoff, chief commercial officer at Enphase Energy. "We are dedicated to innovation, quality, and customer-centered service as we work to unlock a more sustainable future for all."

08:19 EDT Sabre, Almatar Travel Group sign new technology agreement - Almatar Travel Group, a travel company in the Kingdom of Saudi Arabia, and Sabre signed a new technology agreement at the Saudi Tourism Forum in Riyadh, that will see the travel company uses Sabre's industry-leading technology and solutions to help drive operational efficiency, advance its virtual payments strategy and transform travelers experience. Under this agreement, Almatar Travel Group will benefit from Sabre's extensive travel ecosystem including its wide geographic scope and breadth of travel content, which includes air, lodging, ancillary and NDC content. Furthermore, Almatar will access Sabre's portfolio of innovative technology and intelligent platform, Sabre Red 360, which will help enable the travel company to differentiate its offering, compete more effectively, grow faster in the region, and expand its online travel business. Additionally, Almatar will use Sabre's APIs and Automation Hub to help it stay competitive in the dynamic Saudi marketplace.

08:18 EDT PaxMedica holds meeting of Scientific Advisory Board - PaxMedica held a Scientific Advisory Board meeting on March 10-12, 2023. A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder in the United States including: Dr Robert Naviaux, Professor of Medicine, Pediatrics, and Pathology, at the University of California, San Diego Dr. Robert Findling, Chair of the Department of Psychiatry, at Virginia Commonwealth University School of Medicine Dr. Alice Mao, Professor of Psychiatry and Behavioral Sciences, at Baylor College of Medicine Dr. Constance Smith-Hicks, Associate Professor of Neurology at Johns Hopkins University and neurologist and research scientist at the Kennedy Krieger Institute Dr. Andrew J. Cutler, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and Chief Medical Officer, Neuroscience Education Institute Dr. Vladimir Maletic, Clinical Professor, Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine Dr. Michael Aman, Professor Emeritus, The Ohio State University Department of Psychology Dr. Rakesh Jain, Clinical Professor, Department of Psychiatry Texas Tech University School of Medicine - Permian Basin The meeting was hosted by PaxMedica's Chief Medical Officer, Stefan Schwabe, MD, PhD, who commented, "We convened some of the country's leading experts in autism spectrum disorder in support of our efforts to bring suramin to the next phase of clinical trials. We continue to be very excited about studying a product for the potential treatment of the core symptoms of autism spectrum disorder."

08:17 EDT Freehold Royalties appoints Rob King as COO - Freehold Royalties announces two internal promotions within the Company's executive team. Effective April 1, 2023, Rob King will be appointed as COO and Susan Nagy will be appointed as Vice President, Business Development. Mr. King joined Freehold in 2020 as Vice President, Business Development. As COO, Mr. King will provide enhanced senior level leadership in respect of the execution of Freehold's North American strategy. Mr. King will oversee a multidisciplinary team focused on numerous value drivers, with the goal of maximizing the value of our current and future asset base. Nagy will be assuming the role of Vice President, Business Development, previously held by Mr. King. Ms. Nagy has been with Freehold since 2008, holding various positions of increasing seniority including most recently as Director, Business Development.

08:14 EDT InspireMD appoints Andrea Tommasoli as COO - InspireMD announced that it has promoted Andrea Tommasoli to COO. Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since joining InspireMD in November 2020.

08:12 EDT Vaccitech announces interim data from Phase 1b/2 trial of VTP-200 - Vaccitech announced topline interim data from the HPV001 study, a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus, HPV, lesions. "These interim data are a promising step in the right direction, and we look forward to seeing the final data in early 2024. Currently people with persistent HPV infections have no treatment options until they develop high grade lesions. Being told to return for a repeat cervical screening every 6 to 12 months without a treatment option can be frustrating and anxiety-provoking," said Bill Enright, CEO of Vaccitech. "VTP-200 is intended to treat HPV infections, potentially before the virus causes these high-grade lesions." Data from the first 58 women enrolled who reached their 6-month timepoint in the HPV001 placebo-controlled study were reviewed internally and the trial will continue as planned to the 12-month primary endpoint. Immunogenicity results showed high responses, defined as an average greater than 1,000 spot-forming units per million peripheral blood mononuclear cells in an ELISPOT assay, especially to the E1, E2 and E6 antigens. VTP-200 was generally well-tolerated with no product-related grade 3 unsolicited events and no product-related SAEs.

08:11 EDT Timber announces publication of sub-analysis of Phase 2b CONTROL study - Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study in Clinical and Experimental Dermatology, CED, the educational journal of the British Association of Dermatologists. The CONTROL study evaluated TMB-001, a topical isotretinoin formulated using the Company's patented IPEG delivery system, in subjects nine years of age and older with moderate to severe congenital ichthyosis, CI. A total of 33 participants in the CONTROL study were randomized to TMB-001 0.05%, TMB-001 0.1%, or vehicle twice daily, stratified by CI subtype, for 12 weeks. The primary endpoint was the proportion of participants with a 50% or greater reduction versus baseline in Visual Index for Ichthyosis Severity (VIIS) scaling. The key secondary endpoint was a two-grade or greater reduction in Investigator Global Assessment scaling score versus baseline. Adverse events were monitored. In the ITT population, 33%/50%/17% of participants with ARCI and 100%/33%/75% of participants with XLRI who received TMB-001 0.05%/TMB-001 0.1%/vehicle, respectively, achieved VIIS-50. In the per-protocol, PP, population, 100%/33%/17% of participants with recessive congenital ichthyosis, ARCI, and 100%/50%/75% of participants with X-linked recessive ichthyosis, XLRI, who received TMB-001 0.05%/TMB-001 0.1%/vehicle, respectively, achieved VIIS-50. In the intent-to-treat population, improvement of greater than or equal to2-grade IGA score was observed in 33%/50%/0% of participants with ARCI and 83%/33%/25% of participants with XLRI who received TMB-001 0.05%/TMB-001 0.1%/vehicle, respectively. In the PP population, improvement of greater than or equal to2-grade IGA score was observed in 100%/67%/0% of participants with ARCI and 100%/50%/25% of participants with XLRI who received TMB-001 0.05%/TMB-001 0.1%/vehicle, respectively. Most AEs reported were application site reactions and were similarly distributed among both subgroups.

08:08 EDT Enlivex receives IMOH clearance for Phase I/II trial of Allocetra - Enlivex Therapeutics announced that an independent Data and Safety Monitoring Board, DSMB, has completed an interim data review for the first cohort of patients in the Company's ongoing Phase I/II clinical trial of Allocetra in patients with advanced-stage peritoneal metastasis arising from solid tumors as an add-on to the standard of care, SoC, chemotherapy administered via Pressurized Intraperitoneal Aerosol Chemotherapy. The Israeli Ministry of Health, IMOH, also reviewed the interim data and provided regulatory clearance to continue the study and open the study's next cohort. In addition, the safety profile supported a protocol amendment to start new patients in the second cohort with higher initial doses of Allocetra. This IMOH clearance follows a previously-reported IMOH clearance to the Company's second Phase I/II clinical trial, which is evaluating Allocetra as monotherapy and in combination with anti-PD1 checkpoint inhibitors in patients with advanced-stage solid tumors. The DSMB based its review on available safety data for the three enrolled patients in the first cohort, in which two patients received three escalating doses of Allocetra, and one received two escalating doses of Allocetra, once every six weeks as an add-on to SoC chemotherapy delivered to the peritoneum.

08:06 EDT Norwegian Cruise Line CEO Frank Del Rio to retire, Harry Sommer to succeed - Norwegian Cruise Line Holdings announced that Frank Del Rio has decided to retire and step down from his position as the Company's President and CEO, and from its Board of Directors, effective June 30, 2023. Del Rio will serve in a consultant capacity as a Senior Advisor to the Board through 2025. Harry Sommer, who has served as President and CEO of NCL since 2020, has been appointed to succeed Del Rio and will also join the Company's Board of Directors, effective July 1, 2023. David Herrera, who has served as Chief Consumer Sales and Marketing Officer of NCL since 2021, will succeed Sommer as President of NCL, effective April 1, 2023.

08:06 EDT Aziyo receives a Not Substantially Equivalent from FDA for CanGaroo RM - Aziyo Biologics provides an update on its submission to the U.S. Food and Drug Administration, FDA, for the CanGaroo RM Antibacterial Envelope, the Company's next-generation biomaterial envelope. The device is intended to securely hold a cardiac implantable electronic device or neurostimulator, creating a stable environment when implanted in the body. As previously announced, the Company submitted a 510(k) premarket notification for the CanGaroo RM Antibacterial Envelope to the FDA in April 2022. As a combination product containing device and drug components, the filing was reviewed by the Center for Devices and Radiological Health and the Center for Drug Evaluation and Research. On March 16, 2023, the Company received a Not Substantially Equivalent determination from FDA. The notice defined the outstanding items that need to be addressed in order to obtain market clearance. The items relate to drug testing, primarily a request by FDA to modify an in vitro drug release assay employed as a manufacturing control. As a result, the Company does not expect to appeal the decision, as it believes the most expeditious path forward is to work with FDA to provide the additional data requested. "While we are disappointed with the delay, we are gratified that the completed review did not raise any questions surrounding the appropriateness of the pathway or majority of the data submitted to support the filing," said Dr. Randy Mills, President and Chief Executive Officer of Aziyo Biologics. "We have our marching orders and are confident that we can address the FDA's questions promptly."

08:05 EDT Heidmar enters business combination agreement with Home Plate Acquisition - Heidmar has entered into a definitive agreement for a business combination with Home Plate Acquisition Corporation. Upon completion of the proposed transaction, the combined company will operate under the "Heidmar" name and be listed on NASDAQ under the ticker symbol "HMAR". Heidmar offers broad services to shipowners, including tanker pool management, commercial management and time charter trading and is actively expanding into dry bulk pool management, vessel sale and purchase services and technical management services, including environmental compliance. Heidmar currently has 60 vessels under management, including both crude oil and refined petroleum product tankers, with an aggregate capacity of approximately 8.3 million deadweight tons. The transaction values the combined company at a pro forma implied equity value of approximately $261.4M. Assuming the net proceeds from the transaction, including the targeted minimum cash raise of $55M, in a combination of expected PIPE raise and Trust cash, and existing cash on Heidmar's balance sheet, Heidmar is expected to have over $47M of cash at transaction close, which is expected to accelerate and fund its growth in commercial and technical management and shipbroking. The Board of Directors of both Home Plate and Heidmar have unanimously approved the transaction. The transaction will require the approval of the shareholders of Home Plate and is subject to several closing conditions including completion of SEC review, regulatory approvals, a $40M net minimum cash condition and the satisfaction of other customary closing conditions. Pankaj Khanna, CEO of Heidmar, will continue as the CEO of the combined company. Daniel Ciporin, Chairman and CEO of Home Plate, and Jonathan Rosenzweig, Director and CFO of Home Plate, will join the Heidmar Board. Heidmar's existing shareholders are expected to own approximately 65% of the pro forma combined company.

08:03 EDT Digital Turbine, Flexion announce strategic commercial relationship - Flexion and Digital Turbine announced a strategic commercial relationship to grow game developers' audiences on some of the world's largest telecom platforms - boosting app discovery and revenue. Through the partnership with Flexion, mobile game developers will be able to create versions of their games that can be smoothly onboarded to DT Hub with little technical effort required - and enjoy the benefits of an end-to-end store alternative offered by major mobile carriers. The most popular Android games will be supported on DT Hub, enhancing reach. To further maximize revenue and take full advantage of user acquisition opportunities, Flexion will help developers get their games fully integrated with the service.

08:01 EDT Starbucks announces Laxman Narasimhan assumes role of CEO - Starbucks announced, effective today, Laxman Narasimhan has assumed the role of chief executive officer and will join the company's board of directors. Narasimhan was named incoming CEO on September 1, 2022, succeeding company founder and now former CEO, Howard Schultz.

07:50 EDT BioNTech, OncoC4 enter collaboration to develop, commercialize ONC-392 - BioNTech and OncoC4 entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate ONC-392 aims to delete immunosuppressive T cells in the tumor microenvironment, but spare Tregs in healthy tissues. With a potentially differentiated safety profile, ONC-392 may be able to achieve a more effective dosing regimen in the clinic and more successful tumor killing. Data from the ongoing Phase 1/2 trial in patients with advanced solid tumors were presented at SITC in 2022 and 2021, where ONC-392 showed encouraging clinical activity, either as single agent or in combination with pembrolizumab in patients with metastases, particularly those who progressed on immunotherapies targeting PD-1 and CTLA-4. ONC-392 received Fast Track designation from the U.S. Food and Drug Administration as a monotherapy for immunotherapy-resistant non-small cell lung cancer.The data in monotherapy of PD-1-resistant NSCLC support the initiation of a randomized Phase 3 trial which will evaluate ONC-392 as monotherapy against the current standard of care in that indication. The candidate is currently also being evaluated in an additional Phase 2 trial as a combination therapy with pembrolizumab in platinum-resistant ovarian cancer. Under the terms of the agreement, OncoC4 will receive a $200M upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties. BioNTech and OncoC4 will jointly develop ONC-392 as monotherapy and in combination with anti-PD-(L)-1 antibodies in a range of solid tumor indications, including NSCLC, until approval, with the parties equally sharing development costs for such studies. All combinations outside of PD-1 inhibition, in particular all combinations with a compound in BioNTech's pipeline, will be solely developed by BioNTech. BioNTech will hold the exclusive worldwide commercialization rights for any of these products with participation of OncoC4 in certain markets to be negotiated in the future.

07:47 EDT MoonLake Immunotherapeutics announces upcoming 2023 milestones - Top-line results for a Phase 2 trial of sonelokimab in moderate-to-severe HS expected around the end of June 2023 with final read-out by Q4 2023;Completion of patient enrollment and randomization for the ongoing Phase 2 trial of sonelokimab in active PsA expected in Q3 2023; Top-line results for a Phase 2 trial of sonelokimab in active PsA anticipated on schedule at the end of the year

07:37 EDT Kanzhun announces $150M share repurchase program - KANZHUN announced that its board of directors has authorized a new share repurchase program under which the Company may repurchase up to $150M of its shares over the next 12 months.

07:33 EDT Illumina says Icahn's nominees 'lack relevant skills and experience' - Illumina responded to Carl Icahn by stating, in part, "A company of Illumina's value creation potential requires a Board invested and experienced in creating clinical markets, driving operational excellence, harnessing the power of science, and realizing a vision for future growth. Illumina's Board brings extensive and diverse business, financial, operating, regulatory and scientific backgrounds in the life sciences and technology sectors, and have presided over the growth of biotech companies, run public life sciences and technology companies, and brought world-class products to market. The Board is led by an independent chair and all nine members are independent, except for the CEO. The Board and management team have a proven track record of successfully managing the core business, and a plan to resolve the acquisition of GRAIL expeditiously and in a manner that is in the best interests of Illumina's shareholders. Illumina's Board of Directors is committed to maximizing value for all shareholders and has always welcomed constructive engagement with the investment community. Illumina's Nominating/Corporate Governance Committee interviewed each of Icahn's nominees and found that they lacked relevant skills and experience. At this time, shareholders are not required to take any action with respect to Icahn. Illumina will file preliminary materials with respect to the 2023 Annual Meeting of Shareholders in the coming weeks."

07:23 EDT Endeavour Mining announces renewal of normal course issuer bid - Endeavour Mining received approval from the Toronto Stock Exchange to renew its Normal Course Issuer Bid for its share repurchase programme, in order to continue to supplement its minimum progressive dividend. Under the NCIB, Endeavour is entitled to repurchase up to 5% of its total issued and outstanding shares as of 14 March 2023, or 12,387,688 shares, during the 12 month period of the NCIB, and up to 25% of the average daily trading volume for the six months ended 28 February 2023, calculated in accordance with the rules of the TSX for purposes of the NCIB or 134,817 shares during each trading day, excluding purchases made in accordance with the block purchase exemptions under applicable TSX policies. All ordinary shares repurchased under the share repurchase programme will be cancelled. The renewed NCIB will commence on 22 March 2023 and end on 21 March 2024, or such earlier date as Endeavour may complete its purchases pursuant to the notice of intention filed with the TSX. Under Endeavour's prior NCIB, which commenced on 22 March 2022 and ends on 21 March 2023, Endeavour obtained approval to purchase up to a total of 12,458,989 ordinary shares, of which 3,864,238 ordinary shares were purchased at a weighted average price of approximately C$27.56. Endeavour's previously announced automatic share purchase agreement with Stifel Nicolaus Europe will continue to allow for the purchase of ordinary shares, subject to certain trading parameters, at times when Endeavour would not be active in the market due to regulatory close periods, its own internal trading black-out periods, insider trading rules or otherwise. Outside of these periods, ordinary shares may be repurchased in accordance with management's discretion and in compliance with applicable law.

07:12 EDT Kraft Heinz, BEES announce expanded partnership - Kraft Heinz and BEES announced an expanded partnership to propel the B2B marketplace, with the ambition to unlock 1M potential new points of sale across LATAM for the company, specifically to enhance its footprint in Mexico, Colombia and Peru. The new LATAM deal is designed to be the catalyst to help Kraft Heinz realize its Emerging Markets strategy by increasing points of distribution and expanding the number of items available to retailers in the region.

07:09 EDT Ameresco extends partnership with Yorkshire Dales Millennium - Ameresco announced it has extended its partnership with Yorkshire Dales Millennium Trust, YDMT , an independent charity dedicated to supporting the people, landscape and wildlife of this special area. The partnership extension will enable the planting of 1,000 trees and restore species-rich wildlife habitats in the region over the next two years. Through this extended partnership, Ameresco will plant an additional 500 trees in the region. Last year, Ameresco supported the planting of 500 trees through a combination of financial aid and employee volunteer efforts to maintain woodlands in the Yorkshire Dales region. Over the next two years, employee volunteers from Ameresco will continue to work alongside the YDMT team to maintain and plant trees across the woodlands. This effort is designed to offset 80 metric tons of carbon dioxide throughout the next 50 years, which is vital to the wildlife and biodiversity in the region. Ameresco will also contribute to the meadow restoration work of YDMT, creating vital wildflower habitat for threatened pollinator species. "Ameresco's donation and support will help ensure that we are supporting our woodlands in a way that not only counteracts the effects of climate change, but also helps to address the biodiversity crisis, providing habitat for wildlife and breathing space for all," said Rich Hore, YDMT Development Officer. "Additionally, they will be helping us to reverse the decline of meadows for pollinators, something which is vitally important as the UK has lost 97 percent of its meadow habitat."

07:08 EDT Emerita Resources announces assay results from program at La Romanera Deposit - Emerita Resources announces additional assay results from the ongoing 2022 - 2023 delineation drilling program at La Romanera Deposit, part of Emerita's wholly owned Iberian Belt West project. Assays from an additional 14 drill holes have been received. According to Ian Parkinson, EVP Corporate Development for Emerita, "Our team is excited to reach this milestone and start the process of putting together this interim mineral resource estimate. Drilling will continue to expand the resources, however we are confident that we have delineated sufficient mineralization with a tight enough drill spacing to support a robust and significant mineral resource estimate. Metallurgical sampling is expected to commence during the resource estimation phase."

07:07 EDT Cellebrite announces RelativityOne integration for quicker, safer data review - Cellebrite DI announced it will offer its LegalView Physical Analyzer capability as a direct add-on to Relativity's proven SaaS product, RelativityOne, bringing more ease and speed to corporate investigations. Combining the power of Cellebrite LegalView and RelativityOne simplifies and streamlines the inclusion of data from multiple mobile devices into formats for review. "Integrating Cellebrite LegalView with RelativityOne makes increasingly pertinent mobile data available quickly to corporate investigators while conserving resources and removing the time-consuming process of manipulating data into a digestible format," said Ken Basore, General Manager at Cellebrite Enterprise Solutions. "We look forward to seeing the positive impact this integration has on improving the efficiency and effectiveness of legal investigators' workflows."

07:06 EDT American Lithium files PEA report for Tonopah Lithium Claims - American Lithium filed an independent National Instrument 43-101 Technical Report on the Preliminary Economic Assessment for the Tonopah Lithium Claims project located in the Esmerelda lithium district northwest of Tonopah, Nevada. Highlights of the PEA were previously announced on February 1, 2023. The PEA and accompanying Technical Report were completed by DRA Global and Stantec Consulting Services and demonstrate that the TLC project has the potential to become a substantial, long-life producer of low-cost, high purity lithium carbonate. The Company also announces that it has engaged DRA Global as lead engineer for the TLC Preliminary Feasibility Study. As part of the initial PFS work, large diameter diamond core drilling has commenced at TLC with 10 holes planned to target 10-15 tonnes of high grade TLC lithium claystone mineralization. The 10-hole program is spread throughout the proposed PEA mine plan footprint and will provide sufficient quantity and variability of mineralized material for detailed metallurgical and pilot process plant testing later in the year. Simon Clarke, CEO of American Lithium states, "We are extremely pleased to have filed the PEA for TLC which shows the strong economic potential of the Project utilizing best of breed conventional mining and recovery techniques. The report is based on detailed process metallurgical work with robust mining and processing operating and capital costing, which allows us to move directly into our PFS work and should enable us to fast-track that process. We have commenced large diameter drilling at TLC to collect sufficient material for our detailed metallurgical test work to be undertaken in close consultation with DRA, enabling the completion of the PFS and running of pilot operations."

07:05 EDT EnCore Energy's NRC Source Materials license for Dewey-Burdock now effective - EnCore Energy announced that the challengers to the Nuclear Regulatory Commission's granting of a Source Materials License to enCore Energy Corp's wholly-owned subsidiary Powertech have declined to seek review by the U.S. Supreme Court. The NRC license is now final and fully effective.

07:04 EDT Microbix announces investments from Governments of Ontario, Canada - Microbix Biosystems is undertaking further expansions to its capabilities and capacity for manufacturing specialized products relating to diagnostic testing for infectious diseases. The Government of Ontario is supporting the expansions at Microbix's three adjacent sites in Mississauga with a grant of $ 840,000 from the Ontario Together Fund. A separate $ 840,000 of interest-free loan funding has also been provided by the Government of Canada through its FedDev Ontario program. The balance of costs will be provided by Microbix from its current funds or ongoing cash flow. This project has three principal objectives, build and equip further product manufacturing space and capabilities for Microbix's core diagnostics businesses, build and equip new development and quality control laboratory spaces, and commission a Containment Level 3 production suite. The project will be completed in 2024, at which time Microbix will be able to optimally service all its current initiatives and rapidly develop further product lines in its field of business. The project is anticipated to create and support dozens of new life sciences manufacturing, product development, and related jobs in Ontario. Microbix was the recipient of a prior grant from OTF (2020) and prior FedDev Ontario funding (2019). Since its first funding from the two programs, Microbix has created two entirely new product lines comprising dozens of fully-registered medical devices, built many strategic customer relationships and a global distribution network, almost doubled its sales, gone to three facilities from one, nearly doubled its staff, and supported healthcare in Ontario, across Canada, and internationally.

07:03 EDT Hannon Armstrong invests $30M in Bioenergy Devco - Bioenergy Devco, the North American division of BTS Bioenergy, announced a $30M investment by Annapolis-based HASI. Bioenergy Devco is the global leader in the design, engineering, construction, financing, and operation of anaerobic digestion facilities to recycle organic material and produce renewable natural gas. The financing, secured by Bioenergy Devco's Maryland Bioenergy Center - Jessup facility, which operates in Jessup, Maryland, will support the development of anaerobic digestion facilities across the U.S. to bring sustainable organic waste recycling, reductions in greenhouse gas emissions, and a sustainable energy resource to more communities in North America.

07:00 EDT Talos Energy announces $100M share repurchase program - Talos Energy announced that its board of directors approved a $100M share repurchase program of the company's common stock. This approval grants Talos's management the authority to repurchase shares opportunistically in the open market from time to time, in privately negotiated transactions, or by such other means as will comply with applicable state and federal securities laws. This is the company's first authorization for share repurchases since its founding.

06:56 EDT Asensus Surgical gets FDA 510(k) clearance for Senhance Surgical System - Asensus Surgical announced that it has received 510(k) clearance from the FDA for an expanded indication to treat pediatric patients with the Senhance System. The Senhance System is already approved for pediatric patients in the EU and Japan.

06:53 EDT Pinduoduo falls 16% to $76.85 after reporting Q4 results

06:49 EDT Syneos Health announces strategic multi-year agreement with Microsoft - Syneos Health (SYNH) announced a strategic multi-year agreement with Microsoft (MSFT). Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables agile deployment of machine learning supporting the analysis, design and execution of clinical trials and commercial programs worldwide. The multi-year agreement includes collaboration with Microsoft Research and leverages developments from OpenAI. Through this collaboration, Syneos Health will deliver technology and data solutions with Microsoft that accelerate clinical development and elevate commercial performance for biopharma customers.

06:46 EDT Crown Crafts acquires Manhattan Toy for $17M - Crown Crafts announced that it has acquired Manhattan Group, LLC, doing business as Manhattan Toy, and its wholly owned subsidiary Manhattan Toy Europe. The acquisition expands Crown Crafts' presence in the growing category of developmental toys for infants and toddlers. Manhattan Toy's product offerings of plush, dolls and wooden toys will complement Crown Crafts' existing line of Sassy toys. The purchase price for the acquisition is $17M and is subject to customary working capital adjustments. The purchase was funded by a combination of cash on hand and proceeds from the company's line of credit. The term of the line of credit has been extended from July 2025 to July 2028 and its borrowing capacity increased from $26M to $35M. The acquisition is expected to be accretive to earnings and will add approximately $24M annually to the company's net sales. Following the acquisition, the toy category will become the largest product category within the company's business, representing approximately 40% of overall net sales.

06:34 EDT Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial - Karuna Therapeutics announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in Positive and Negative Syndrome Scale total score compared to placebo at Week 5. Consistent with prior trials, KarXT demonstrated an early and sustained statistically significant reduction of symptoms from Week 2 through the end of the trial as assessed by PANSS total score. The NDA submission for KarXT in schizophrenia will incorporate the efficacy and safety data from the three placebo-controlled registrational trials, EMERGENT-1, EMERGENT-2, and EMERGENT-3, in addition to long-term safety data from the ongoing EMERGENT-4 and EMERGENT-5 trials. The company is on track to submit an NDA to the FDA in mid-2023, with a potential launch in the second half of 2024, if approved.

06:12 EDT Proterra reaches binding letter of intent with Cowen convertible note holders - Proterra announced that the Proterra Operating Company has reached a binding letter of intent with CSI GP I LLC and its affiliates that sets forth proposed amendments to the Note Purchase Agreement, dated as of August 4, 2020, by and among Proterra Operating Company, the investors and guarantors from time to time party thereto and CSI GP I LLC, as collateral agent, and the convertible notes issued to the Cowen Parties pursuant thereto. The parties intend to enter into definitive agreements reflecting the terms in the binding letter of intent.

06:03 EDT Standard Lithium commences drilling at South West Arkansas Lithium Project - Standard Lithium announced the commencement of a drilling program at its South West Arkansas Lithium Project to support the forthcoming Preliminary Feasibility Study. The drilling program will inform the resource definition and de-risk the resource estimate, provide additional porosity and permeability data through the entire thickness of the productive zones in the Smackover Formation, and optimize production-wellfield design. The drilling program covers two new locations and three re-entries of plugged and abandoned oil and gas wells. The drilling program will continue through Q2 until completed, though not all the data collected will be required for the forthcoming PFS.

05:34 EDT MasterCard acquires Baffin Bay Networks, terms undisclosed - Mastercard acquired cloud-based cybersecurity company Baffin Bay Networks. Baffin Bay Networks, based in Sweden, adds to Mastercard's multi-layered approach to cyber security and helps to stop attacks, while mitigating exposure to risk across the ecosystem. The acquisition further strengthens Mastercard's broader services offerings and value beyond the payment transaction. To counter threats, Mastercard will integrate its solutions into a single cyber service available to all its customers across the world. Its existing RiskRecon data analytics enables organizations to identify vulnerabilities in advance. Customers will now benefit from Baffin Bay's automated Threat Protection service which helps to stop attackers from penetrating or taking down cyber systems.

05:22 EDT Genentech announces long-term data for Evrysdi in SUNFISH study - Genentech, a member of Roche, announced new long-term data for Evrysdi in a broad range of people aged 2-25 years with spinal muscular atrophy, or SMA, from the pivotal SUNFISH study. Data confirm increases in motor function were sustained at four years and the overall rate of adverse events continued to decrease over the 48-month period, reinforcing the long-term efficacy and safety of Evrysdi. Participants also reported continuous improvement or stabilization when independently performing activities of daily living such as picking up and moving objects. The data were presented at the Muscular Dystrophy Association, or MDA, Clinical and Scientific Conference, March 19-22. The increase in motor function from baseline observed during the first year of the study was maintained through the fourth year of treatment with Evrysdi, as measured by changes in Motor Function Measure 32 and Revised Upper Limb Module. Without treatment, natural history data show that patients with Type 2 or 3 SMA typically show a decline in motor function over time. Evrysdi was well tolerated over the four-year time period. Adverse events, or AEs, and serious adverse events, or SAEs, were reflective of the underlying disease. The most commonly reported AEs include headache, fever and upper respiratory tract infection. No treatment-related AEs led to withdrawal from the study. In addition to bringing Evrysdi to people around the world, Genentech also leads its clinical development as part of a collaboration with the SMA Foundation and PTC Therapeutics. Genentech is currently investigating Evrysdi in combination with an anti-myostatin molecule targeting muscle growth in the Phase II/III trial MANATEE for the treatment of SMA.

05:16 EDT Blackstone opens new office in Frankfurt - Blackstone announced that it will open a new office in Frankfurt, Germany. The new flagship location will occupy 1,300 square meters in the Omniturm in Frankfurt's financial district and serve as a hub for Blackstone in Germany. The new office will host professionals across Blackstone's private equity, real estate, and credit businesses, in addition to providing a hub for Blackstone's private wealth solutions business, which serves investment professionals and individual investors across Europe. Blackstone has been an active and significant investor in Germany for more than two decades, with currently more than 7,000 people employed by its portfolio companies in the country. To date, the firm has been involved in transactions worth more than EUR 17B in Germany.